Home > Oncology > ESMO 2020 > Lung Cancer > First-line immune checkpoint inhibition in metastatic NSCLC

First-line immune checkpoint inhibition in metastatic NSCLC

ESMO 2020
Long-term follow up of KEYNOTE-024 and the first results of EMPOWER-Lung 1 demonstrated that pembrolizumab and cemiplimab, both anti-PD-1 antibodies, are effective as first-line monotherapy in metastatic NSCLC. Pembrolizumab was the first anti-PD-1 antibody monotherapy to improve survival in patients with metastatic NSCLC in first line [1]. At 5-year follow-up, 99/150 (66%) patients treated with chemotherapy had crossed over to pembrolizumab, whereas 80/154 (52%) of patients in the pembrolizumab group received subsequent anti-cancer therapy including 12 who received a second course of pembrolizumab [2]. Reported 5-year overall survival (OS) rate in the pembrolizumab arm was 31.9% versus 16.3% in the chemotherapy arm, despite 66% cross-over. Progression-free survival (PFS) rate at 5 years was 22.8% and 4.1%, respectively. Objective response rate (ORR) in the patients treated with pembrolizumab was 46.1% (4.5% complete, 41.6% partial response) versus 31.1% (...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on